There are fresh fears that the AstraZeneca and Johnson & Johnson Covid-19 jabs could cause a terrifying spinal inflammation on rare occasions.
The European Medicines Agency wants to put warning labels on the two vaccines stating there was a “reasonable possibility” that it could cause the rare side effect.
Following three days of discussions and meetings, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) said it wanted to include a warning for “very rare cases of transverse myelitis (TM) reported following vaccination”.
It is also adding the condition as an “adverse reaction of unknown frequency” to the vaccine profile.
The EMA described TM as a rare neurological condition characterised by “inflammation of one or both sides of the spinal cord”.
It can terrifyingly cause weakness in arms or legs, tingling, numbness, pain – and problems with bowel and bladder function.
The recommendation comes after the PRAC analysed reported cases worldwide and scientific literature, RT reports.
They concluded: “A causal relationship between these two vaccines and transverse myelitis is at least a reasonable possibility.” However, it said the “benefit-risk profile of both vaccines remains unchanged.”
It hopes to “raise awareness among healthcare professionals and people receiving the vaccines.”
Doctors have been told to be on the look out for symptoms and signs of TM, while recipients were urged to “seek immediate medical attention” if they develop the symptoms.
To stay up to date with all the latest news, make sure you sign up to one of our newsletters here.
The EMA last month approved the Janssen jab as a booster for people aged 18 and older, to be given at least two monthys after previous vaccinations.
The AstraZeneca vaccine, developed with Oxford University, has been scaled back on usage due to the “ultra rare” side effect of blood clotting.
In other Covid news, an experimental new nasal spray could prevent people from getting infected with Covid-19 for up to eight hours, according to a study.
The New York Times reported that the promising treatment has shown it can block infection from the virus in lab studies with mice, according to researchers at the University of Helsinki in Finland.
Study author Kalle Saksela told Gizmodo that “this technology is cheap and highly manufacturable, and the inhibitor works equally well against all variants.”
She added: “It works also against the now-extinct SARS virus, so it might well also serve as an emergency measure against possible new coronaviruses.”